SCHEMBL6404607

SCHEMBL6404607

COc1cc(C=C2C(=O)Nc3ccccc32)c(-c2ccccc2OC)cc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.74
MDM2 Q00987 1/20 0.66
CSNK1D P48730 3/20 0.62
CSNK1A1 P48729 3/20 0.62
CSNK1E P49674 2/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
GMNN O75496 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
TP53 P04637 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C9 P11712 1/20 0.62
HPGD P15428 1/20 0.62
MAPK1 P28482 1/20 0.62
CYP2C19 P33261 1/20 0.62
THPO P40225 1/20 0.62
RAB9A P51151 1/20 0.62
BLM P54132 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6404603 1.00 NPC1 (0.74) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL6407911 0.91 NPC1 (0.62) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL14448926 0.88 NPC1 (0.75) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL5482740 0.88 NPC1 (0.75) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL5482745 0.88 NPC1 (0.75) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL29367529 0.85 NPC1 (1.00) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL5469692 0.85 NPC1 (1.00) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL5469690 0.85 NPC1 (1.00) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL16442345 0.85 NPC1 (1.00) NPC1MDM2CSNK1DCSNK1A1CSNK1E
SCHEMBL6391514 0.83 MDM2 (0.61) NPC1MDM2CSNK1DCSNK1A1CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US claimed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 WO claimed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO claimed
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 US disclosed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 WO disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 NPC1 3867/4885MDM2 824/4885CSNK1D 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.